Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18256622 | 0.87 | SMN1; SMN2 (0.49) | LMNASMN1; SMN2KMT2APOLBTRPA1 | |
| SCHEMBL18256710 | 0.82 | KMT2A (0.51) | LMNAKMT2APOLBTRPA1HIF1A | |
| SCHEMBL18256643 | 0.78 | ADORA2B (0.56) | LMNASMN1; SMN2POLBRXFP1 | |
| SCHEMBL18256623 | 0.78 | KMT2A (0.43) | LMNAKMT2APOLBTRPA1HIF1A | |
| SCHEMBL20205787 | 0.77 | LMNA (0.42) | LMNASMN1; SMN2KMT2APOLBRXFP1 | |
| SCHEMBL20205786 | 0.77 | KMT2A (0.46) | LMNAKMT2APOLBRXFP1TRPA1 | |
| SCHEMBL18256066 | 0.74 | KMT2A (0.60) | LMNASMN1; SMN2KMT2APOLBRXFP1 | |
| SCHEMBL20205697 | 0.74 | KMT2A (0.47) | LMNASMN1; SMN2KMT2APOLBRXFP1 | |
| SCHEMBL19601312 | 0.69 | KMT2A (0.50) | LMNASMN1; SMN2KMT2APOLBRXFP1 | |
| SCHEMBL18256704 | 0.68 | TNF (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | LMNA 2283/4885SMN1; SMN2 1801/4885KMT2A 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.